254 related articles for article (PubMed ID: 9701244)
1. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Bajou K; Noël A; Gerard RD; Masson V; Brunner N; Holst-Hansen C; Skobe M; Fusenig NE; Carmeliet P; Collen D; Foidart JM
Nat Med; 1998 Aug; 4(8):923-8. PubMed ID: 9701244
[TBL] [Abstract][Full Text] [Related]
2. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.
Maillard C; Jost M; Rømer MU; Brunner N; Houard X; Lejeune A; Munaut C; Bajou K; Melen L; Dano K; Carmeliet P; Fusenig NE; Foidart JM; Noel A
Neoplasia; 2005 Jan; 7(1):57-66. PubMed ID: 15720817
[TBL] [Abstract][Full Text] [Related]
3. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
Lambert V; Munaut C; Noël A; Frankenne F; Bajou K; Gerard R; Carmeliet P; Defresne MP; Foidart JM; Rakic JM
FASEB J; 2001 Apr; 15(6):1021-7. PubMed ID: 11292663
[TBL] [Abstract][Full Text] [Related]
4. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
5. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.
Bajou K; Maillard C; Jost M; Lijnen RH; Gils A; Declerck P; Carmeliet P; Foidart JM; Noel A
Oncogene; 2004 Sep; 23(41):6986-90. PubMed ID: 15286708
[TBL] [Abstract][Full Text] [Related]
6. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
8. Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.
Jost M; Maillard C; Lecomte J; Lambert V; Tjwa M; Blaise P; Alvarez Gonzalez ML; Bajou K; Blacher S; Motte P; Humblet C; Defresne MP; Thiry M; Frankenne F; Gothot A; Carmeliet P; Rakic JM; Foidart JM; Noël A
Am J Pathol; 2007 Oct; 171(4):1369-80. PubMed ID: 17717143
[TBL] [Abstract][Full Text] [Related]
9. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
10. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
Bajou K
Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
12. Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.
Masset A; Maillard C; Sounni NE; Jacobs N; Bruyére F; Delvenne P; Tacke M; Reinheckel T; Foidart JM; Coussens LM; Noël A
Int J Cancer; 2011 Jan; 128(2):283-93. PubMed ID: 20232379
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
Inoue M; Sawada T; Uchima Y; Kimura K; Nishihara T; Tanaka H; Yashiro M; Yamada N; Ohira M; Hirakawa K
Oncol Rep; 2005 Dec; 14(6):1445-51. PubMed ID: 16273237
[TBL] [Abstract][Full Text] [Related]
14. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
Devy L; Blacher S; Grignet-Debrus C; Bajou K; Masson V; Gerard RD; Gils A; Carmeliet G; Carmeliet P; Declerck PJ; Nöel A; Foidart JM
FASEB J; 2002 Feb; 16(2):147-54. PubMed ID: 11818362
[TBL] [Abstract][Full Text] [Related]
15. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.
Mueller MM; Fusenig NE
Differentiation; 2002 Dec; 70(9-10):486-97. PubMed ID: 12492491
[TBL] [Abstract][Full Text] [Related]
16. The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma.
Hanekom GS; Stubbings HM; Kidson SH
Cancer Detect Prev; 2002; 26(1):50-9. PubMed ID: 12088203
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
Ma D; Gerard RD; Li XY; Alizadeh H; Niederkorn JY
Blood; 1997 Oct; 90(7):2738-46. PubMed ID: 9326241
[TBL] [Abstract][Full Text] [Related]
18. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
19. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
20. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
Soff GA; Sanderowitz J; Gately S; Verrusio E; Weiss I; Brem S; Kwaan HC
J Clin Invest; 1995 Dec; 96(6):2593-600. PubMed ID: 8675623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
